<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04028739</url>
  </required_header>
  <id_info>
    <org_study_id>TC_BA</org_study_id>
    <nct_id>NCT04028739</nct_id>
  </id_info>
  <brief_title>Theracurmin vs Curcumin Bioavailability Study</brief_title>
  <official_title>A Randomized, Open-label, Cross-over, Single Administration Study to Compare Bioavailability of Curcumin in Health Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, cross-over, single administration study to compare bioavailability
      of curcumin in health adults
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Randomization, Open-label, 3-period, 6-sequence, Crossover, Single

        -  Drug-free inverval : more than 7 days

        -  Sampling time : 0,0.5,1,1.5,2,3,4,6,8,12h
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Actual">November 29, 2019</completion_date>
  <primary_completion_date type="Actual">November 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>12hours</time_frame>
    <description>Maximum concentration at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>12hours</time_frame>
    <description>Area under the concentration-time curve at steady state</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Theracurmin CR-033P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Capsule with 150mL water, Single, curcumin 90mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Theracurmin CR-031P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Capsule with 150mL water, Single, curcumin 90mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Capsule with 150mL water, Single, curcumin 90mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>curmin</intervention_name>
    <description>curcumin 90mg/day cross-over</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Theracurmin CR-031P</arm_group_label>
    <arm_group_label>Theracurmin CR-033P</arm_group_label>
    <other_name>Theracurmin CR-033P</other_name>
    <other_name>Theracurmin CR-031P</other_name>
    <other_name>Curcumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult 19 to 60 years

          2. BMI 18.0~30.0kg/m2 at screening

          3. Subject who was given, and fully understood, the information about the study, and has
             provided voluntary written informed consent to participate in the study and agreed to
             comply with the study requirements.

        Exclusion Criteria

          1. A person with clinically significant disease corresponding to cardiovascular,
             respiratory, liver, kidney, digestive system, blood/tumor system, endocrine system,
             immune system, neuropsychiatry or who has a history within the last 6 months.

          2. A person with a history of gastrointestinal disease or surgery (except for simple
             cecal surgery or hernia surgery) that may affect the absorption of food for clinical
             research.

          3. Persons who have an irritable reaction to foods containing turmeric or other drugs and
             food.

          4. Those who took medicines within 7 days before the first intake of food for clinical
             research.

          5. Food for Clinical Research If you have consumed foods containing turmeric (eg,
             radishes, curry) within 7 days before the first intake of food, or you can't consume
             until the day of intake of food for the last clinical study.

          6. Those who have participated in other clinical studies within 90 days prior to the
             first intake of food for clinical research.

          7. Women who are pregnant or lactating during screening, or who plan to become pregnant
             during clinical research. A person who is deemed unsuitable for participating in this
             clinical study because of other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyewon Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea Kuro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

